Curasight announces appointment of Dr. Kirsten Drejer as new board member
Curasight A/S (“Curasight”) is pleased to add a prominent and experienced biotech profile to its Board of Directors.Kirsten Drejer holds a PhD in pharmacology and has been involved in drug development throughout her career. She is probably best known as co-founder and CEO of Symphogen A/S for 16 years. During her leadership at Symphogen A/S, she raised more than 300 million EUR from premier international investors, 250 million EUR through partnerships and grew the company to become one of the most successful biotech companies within oncology with more than 100 employees. Dr. Drejer